ReviewDrugs2006
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.World journal of urology · 2019Pooled it
- Korean clinical practice guideline for benign prostatic hyperplasia.Investigative and clinical urology · 2016Guideline
- Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.World journal of urology · 2015Trial
- Sexuality and the management of BPH with alfuzosin (SAMBA) trial.International journal of impotence researchTrial
- Temporary pharmacologically induced ejaculatory dysfunction influences surgical decision-making in sexually active men with benign prostatic hyperplasia: a prospective interventional study.International urology and nephrology · 2026Article
- Systemic alpha-1 adrenergic receptor inhibition reduces sperm damage in adult and aging spontaneously hypertensive rats.Scientific reports · 2024Article
- AlphaNaunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Adrenoceptors in the Lower Urinary Tract.Handbook of experimental pharmacology · 2024Review
- Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques.Life (Basel, Switzerland) · 2023Review
- Immunolocalization of Adrenoceptors in the Reproductive Tract of Male Domestic Cats in Comparison to Rats.Animals : an open access journal from MDPI · 2021Article
- Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia-related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity.Prostate international · 2020Article
- [Benign prostatic hyperplasia : New and treatment-relevant aspects from the DGU guidelines].Der Urologe. Ausg. A · 2020Review
- The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health.Current urology reports · 2019Review
- Urologists' attitudes to sexual complications of LUTS/BPH treatments.World journal of urology · 2018Article
- Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.Current cardiology reports · 2017Review
- Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination.Asian journal of urology · 2017Review
- [Bladder storage and voiding dysfunctions : Side effects of drug therapy].Der Urologe. Ausg. A · 2017Review
- The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.Translational andrology and urology · 2017Review
- The Effect of LUTS/BPH and Treatments on Ejaculatory Function.Current urology reports · 2016Review
- Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia.Therapeutic advances in urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
alpha(1)-Adrenoceptor antagonists such as alfuzosin, doxazosin, tamsulosin and terazosin are first-line agents for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH), but are only second-line agents (doxazosin and terazosin only) for the treatment of arterial hypertension. Sexual function is complex and includes multiple domains such as sexual desire (libido), erectile function and ejaculatory function. Erectile and ejaculatory functions are frequently reduced in patients with BPH and can impact on their quality of life. Therefore, the treatment of BPH should aim to maintain or even restore sexual function.alpha(1)-Adrenoceptor antagonists lack major effects on sexual desire in placebo-controlled studies. Reports on erectile function are inconsistent, with both beneficial and adverse effects being reported, but impotence can occur in some patients without clear differences between drugs. Ejaculatory dysfunction during treatment may represent (relative) an ejaculation. It occurs more frequently with tamsulosin than with other drugs of this class, but the differences are not big enough to be consistently detectable in directly comparative studies. We propose that such differences between drugs should be weighed against differences in cardiovascular tolerability when choosing the optimal treatment for each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.